Get the Daily Brief
Latest Biotech News
Protein and Proteomics Research Illuminate Neurodegenerative Disease Mechanisms
The Global Neurodegeneration Proteomics Consortium released one of the world’s largest dementia-related protein datasets containing about 250 million protein measurements from over 35,000 samples...
Novel Microbiome Metabolite Identified as Driver and Therapeutic Target in Atherosclerosis
New research from the Centro Nacional de Investigaciones Cardiovasculares (CNIC) identifies imidazole propionate (ImP), a gut microbiota-derived metabolite, as associated with early active...
Brain Blood Flow Mechanism Decoded in Mice: Connexin Proteins Key
Scientists from Harvard Medical School, the Broad Institute, and Weill Cornell Medicine have elucidated how the brain rapidly redirects blood flow to active regions. Utilizing optogenetics and...
Sarepta Therapeutics Restructures After DMD Therapy Safety Setbacks
Sarepta Therapeutics is cutting approximately 36% of its workforce—about 500 jobs—following the deaths of two Duchenne muscular dystrophy patients treated with its gene therapy Elevidys. The...
Eight Healthy Babies Born via Mitochondrial Donation Trial in UK
UK researchers announced the birth of eight infants conceived through mitochondrial donation using pronuclear transfer, preventing transmission of mitochondrial DNA disease. This technique...
Non-Antibiotic Drugs Disrupt Gut Microbiome’s Pathogen Defense
Recent studies reveal that common non-antibiotic medications can impair the gut microbiome's ability to resist colonization by harmful pathogens. This disruption may arise through alterations in...
GLP-1/GIP Dual Agonist Shows Significant Weight Loss in China Phase III Trial
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics reported that their dual-acting GLP-1/GIP receptor agonist induced nearly 18% mean weight loss at 48 weeks in obese patients during a Phase...
FDA Scrutiny of GSK’s Blenrep Questions Safety and Efficacy Ahead of Advisory Panel
Ahead of the July 17 advisory committee meeting, FDA reviewers expressed concerns over GSK's antibody-drug conjugate Blenrep’s ocular toxicity, high rates of dose modifications, and unclear...
Nuclidium Raises $98M Series B to Advance Copper-Based Radiotheranostics
Swiss-German radiopharmaceutical company Nuclidium closed a $98 million Series B financing to accelerate development and production of its copper-61 and copper-67 radiotheranostic agents for...
Biotx AI Uses GWAS Data for Drug Target Discovery and Repurposing
German startup Biotx AI leverages a vast curated genome-wide association study (GWAS) dataset with phenotypic and drug molecule data to predict disease causality and identify optimal drug targets....
Large-Scale Neurodegeneration Proteomics Consortium Identifies Biomarkers and Mechanisms
The Global Neurodegeneration Proteomics Consortium (GNPC) released one of the largest proteomic datasets comprising approximately 250 million protein measurements from over 35,000 biosamples....
CalPERS Switches Pharmacy Benefit Manager to CVS Caremark for 587,000 Members
California Public Employees’ Retirement System (CalPERS) has signed a five-year contract with CVS Caremark to provide outpatient prescription drug benefits for approximately 587,000 members...
Sarepta restructures and adds black box warning on Duchenne therapy
Sarepta Therapeutics is undergoing a major restructuring by laying off approximately 500 employees, about 36% of its workforce, and pausing research on several gene therapy programs for...
Hengrui and Kailera’s dual agonist shows strong obesity trial results in China
Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced promising Phase 3 results for their injected glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide...
FDA scrutiny and advisory for GSK's multiple myeloma drug Blenrep
The US Food and Drug Administration has raised safety concerns regarding GSK's antibody-drug conjugate Blenrep (belantamab mafodotin) for multiple myeloma patients, focusing on ocular toxicities...
Merck expands respiratory portfolio with Verona Pharma acquisition
Merck & Co. has acquired Verona Pharma for $10 billion, securing rights to Ohtuvayre, a novel respiratory drug approved in 2024 for chronic obstructive pulmonary disorder (COPD). The drug relaxes...
Advances in neurodegeneration proteomics reveal disease mechanisms and biomarkers
The Global Neurodegeneration Proteomics Consortium (GNPC) published findings from one of the largest proteomic datasets, comprising approximately 250 million unique protein measurements from over...
New AI and computational platforms boost biomanufacturing optimization
Researchers and industry leaders are advancing biomanufacturing through agentic AI and digital twin technologies to overcome current limitations. Systems like SIC (sense, infer, and control)...
FDA tightens oversight amid staffing cuts and controversial decisions
The FDA faces significant staffing challenges with over 380 departures at the Center for Drug Evaluation and Research between January and June 2025, alongside minimal new hires. This attrition...
Open-source molecular diagnostics improve testing accessibility in low-resource areas
International scientists developed an affordable, lyophilized reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for pathogen detection aimed at resource-limited...